Dr. Thomas Dietz
News from Transcept Pharmaceuticals next, as Dr. Thomas Dietz, Chairman and CEO of Waypoint Holdings, joins the board as an independent director.
According to Glenn Oclassen, CEO of Transcept, with over 20 years in the biopharma realm “the addition of Tom Dietz further enhances the Board's already strong pharmaceutical industry expertise.”
He continued to say: "Tom brings a track-record of success and deep industry knowledge, and his viewpoint and advice will be important as we move through the next stage of our corporate development."